Nexalin Technology, Inc. NXL 深 沪
等待开盘 12-23 09:30:00 美东时间
0.7902
-0.041
-4.99%
华盛通- 最 高0.83
- 今 开0.83
- 成交量 17.52万股
- 最 低 0.79
- 昨 收 0.8317
- 总市值 1357.40万
- 52周最高 3.87
- 市盈率 静 --
- 换手率 1.02%
- 52周最低 0.702
- 委 比 -81.82%
- 总股本 1717.79万
- 历史最高 4.4899
- 量 比 3.30
- 振 幅 4.81%
- 历史最低 0.2528
- 每 手 1
- 风险率 0.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
Nexalin Technology, Inc. (Nasdaq: NXL) invites investors to a webinar on December 4, 2025, at 4:15 p.m. ET, hosted by RedChip Companies. CEO Mark White will discuss Nexalin's innovative Deep Intracranial Frequency Stimulation (DIFS™) technology for mental healthcare, clinical evidence, and updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model. Nexalin, with international regulatory approvals and U.S. expansion underway, targets the ...
12-02 13:00
Nexalin Technology Signs Exclusive Distribution Agreement With Carmi Masha Technologies To Advertise, Sell Nexalin's Gen-2 Console In Israel
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution
11-13 22:21
Nexalin Technology Receives Approval To Sell Its Gen-2 Console Device In Israel
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its Gen-2 Console ("SYNC"), 15 milliamp (mA)
10-30 20:31
Nuix Withdraws CEO Performance Rights Resolutions Amid Leadership Change
Nuix Ltd. ( ($AU:NXL) ) just unveiled an announcement. Nuix Limited has announc...
10-27 14:27
Nuix Appoints John Ruthven as Interim CEO
Nuix Ltd. ( ($AU:NXL) ) has issued an update. Nuix Limited has announced the ap...
10-27 07:18
Nuix CEO Jonathan Rubinsztein to Step Down
Nuix Ltd. ( ($AU:NXL) ) has issued an update. Nuix Limited announced that its C...
10-27 07:17
Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
Three independent studies published in *Alzheimer's Research & Therapy*, *Journal of Alzheimer's Disease*, and *Radiology* validate Nexalin's non-invasive DIFS™ technology, demonstrating significant cognitive and neuroimaging benefits in Alzheimer's patients. The studies highlight improvements in memory, brain connectivity, and network功能, positioning Nexalin as a potentially paradigm-shifting, drug-free solution with fewer risks and costs compare...
10-21 13:00
Nexalin Technology Amends Equity Distribution Agreement
An announcement from Nexalin Technology, Inc. ( ($NXL) ) is now available. On O...
10-16 05:17
Nuix Ltd. Issues 50,000 Performance Rights in Employee Incentive Scheme
Nuix Ltd. ( ($AU:NXL) ) has provided an update. Nuix Ltd. announced the issuanc...
10-13 12:17
